MX2024009317A - Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidores punto de control. - Google Patents
Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidores punto de control.Info
- Publication number
- MX2024009317A MX2024009317A MX2024009317A MX2024009317A MX2024009317A MX 2024009317 A MX2024009317 A MX 2024009317A MX 2024009317 A MX2024009317 A MX 2024009317A MX 2024009317 A MX2024009317 A MX 2024009317A MX 2024009317 A MX2024009317 A MX 2024009317A
- Authority
- MX
- Mexico
- Prior art keywords
- ntsr1
- combination therapy
- checkpoint inhibitor
- inhibitor combination
- targeted radiopharmaceuticals
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title abstract 2
- 229940121896 radiopharmaceutical Drugs 0.000 title abstract 2
- 239000012217 radiopharmaceutical Substances 0.000 title abstract 2
- 230000002799 radiopharmaceutical effect Effects 0.000 title abstract 2
- 101000591385 Homo sapiens Neurotensin receptor type 1 Proteins 0.000 abstract 1
- 102000017921 NTSR1 Human genes 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Las terapias de combinación comprenden administrar radiofármacos dirigidos a NTSR1 y uno o más inhibidores de punto de control.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263304173P | 2022-01-28 | 2022-01-28 | |
| PCT/CA2023/050114 WO2023141722A1 (en) | 2022-01-28 | 2023-01-27 | Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009317A true MX2024009317A (es) | 2024-08-06 |
Family
ID=87469972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009317A MX2024009317A (es) | 2022-01-28 | 2023-01-27 | Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidores punto de control. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250099633A1 (es) |
| EP (1) | EP4469093A1 (es) |
| JP (1) | JP2025503213A (es) |
| KR (1) | KR20240142498A (es) |
| CN (1) | CN118922214A (es) |
| AR (1) | AR128381A1 (es) |
| AU (1) | AU2023211720A1 (es) |
| IL (1) | IL314533A (es) |
| MX (1) | MX2024009317A (es) |
| TW (1) | TW202337450A (es) |
| WO (1) | WO2023141722A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2740726A1 (en) * | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin receptor ligands |
| CN111565762A (zh) * | 2017-11-10 | 2020-08-21 | 威斯康星校友研究基金会 | 使用靶向放射治疗(trt)来驱动对免疫疗法的抗肿瘤免疫反应 |
| EP3897725A4 (en) * | 2018-12-21 | 2022-11-30 | Actinium Pharmaceuticals, Inc. | COMBINATION OF RADIOIMMUNOTHERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF CANCER |
-
2023
- 2023-01-27 IL IL314533A patent/IL314533A/en unknown
- 2023-01-27 MX MX2024009317A patent/MX2024009317A/es unknown
- 2023-01-27 EP EP23745777.5A patent/EP4469093A1/en active Pending
- 2023-01-27 WO PCT/CA2023/050114 patent/WO2023141722A1/en active Application Filing
- 2023-01-27 AU AU2023211720A patent/AU2023211720A1/en active Pending
- 2023-01-27 CN CN202380029884.0A patent/CN118922214A/zh active Pending
- 2023-01-27 JP JP2024544708A patent/JP2025503213A/ja active Pending
- 2023-01-27 US US18/833,848 patent/US20250099633A1/en active Pending
- 2023-01-27 KR KR1020247028702A patent/KR20240142498A/ko active Pending
- 2023-01-30 TW TW112103191A patent/TW202337450A/zh unknown
- 2023-01-30 AR ARP230100210A patent/AR128381A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023211720A1 (en) | 2024-08-15 |
| US20250099633A1 (en) | 2025-03-27 |
| JP2025503213A (ja) | 2025-01-30 |
| CN118922214A (zh) | 2024-11-08 |
| TW202337450A (zh) | 2023-10-01 |
| KR20240142498A (ko) | 2024-09-30 |
| EP4469093A1 (en) | 2024-12-04 |
| IL314533A (en) | 2024-09-01 |
| AR128381A1 (es) | 2024-04-24 |
| WO2023141722A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001433A1 (es) | Terapia de combinación de radioinmunoconjugados con inhibidor del punto de control | |
| BR112022011421A2 (pt) | Inibidores da proteína mutante kras | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| AR126128A1 (es) | Terapia de combinación de radioinmunoconjugados e inhibidores de puntos de control | |
| MX377351B (es) | Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico | |
| IL311376A (en) | Azetidine and pyrrolidine parp1 inhibitors and uses thereof | |
| MA54118A (fr) | Polythérapie utilisant une thérapie cellulaire adoptive et un inhibiteur de point de contrôle | |
| EA201890728A3 (ru) | Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами | |
| EP4351552A4 (en) | COMBINATION THERAPIES WITH SETD2 INHIBITORS | |
| MX2022004259A (es) | Inhibidores de mek para el tratamiento de infecciones por hantavirus. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| MA55799A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 | |
| MX2024009317A (es) | Radiofarmacos dirigidos a ntsr1 y terapia de combinacion de inhibidores punto de control. | |
| MX2024009313A (es) | Radiofarmacos dirigidos al psma e inhibidor de punto de control. | |
| IL281450A (en) | Plasminogen activator inhibitor 1 (PAI-1) inhibitors and uses thereof | |
| MX2018000984A (es) | Terapias de combinacion. | |
| AR125356A1 (es) | Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4 | |
| MX2020011912A (es) | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). | |
| EP3930719A4 (en) | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors | |
| BR112022005855A2 (pt) | Método para tratar transtorno de humor | |
| JOP20220073A1 (ar) | استخدام مثبطات fgfr في السرطانات المعدلة جينيا بـ fgfr لتحسين استجابة المريض لتحصين مثبطات نقطة الفحص في أوضاع علاجية تتابعية | |
| AU2023901717A0 (en) | Combination therapy with checkpoint inhibitors | |
| BR112022024806A2 (pt) | Compostos de espirolactama e métodos de tratamento de infecções virais com sua utilização | |
| HK40109325A (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| HK40109328A (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy |